A Phase 4 interventional study of OnabotulinumtoxinA 100 UNT [Botox] and Sodium Chloride 0.9% for Injection, Preservative Free in Trigeminal Neuralgia, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Stanford University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is the 16th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 4, reaches primary completion later than 4 of the 10 other live ones, and was the 33rd registered.
140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.
Browse Trigeminal Neuralgia studies →7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
The Radiosurgery Society · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 93 interventional studies indexed under Trigeminal Neuralgia.
Median enrollment 29 across the 26 interventional studies, 56 across the 8 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 4 studies filed under Trigeminal Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Trigeminal Neuralgia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05217628Phase 3Noema Pharma AGAn Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | 2027-02-02 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT06216886Stanford UniversityOnabotulinumtoxinA for Trigeminal Neuralgia | 2027-02-01 |
| NCT05269472University of MinnesotaTrigeminal Neuralgia Electrophysiology | 2027-11-01 |
| NCT05738096University of MinnesotaTrigeminal Evoked Responses to Improve Rhizotomy | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
This study will offer onabotulinumtoxin A (Botox) delivered intradermally into the region of pain for the patient with trigeminal neuralgia. Should they derive benefit from the procedure (as determined by decrease in the frequency of attacks), then they will be randomized to receive either onabotulinumtoxin A or saline and followed for 3 months. This study hopes to provide strong data that this is a treatment option for patients with TN who have failed medications, but are not ready for or do not want to undergo surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men and women age 18 or older
Exclusion Criteria:
Intradermal injections will be placed in the affected trigeminal territories according to a specific facial map that we have developed.
Drug: OnabotulinumtoxinA 100 UNT [Botox]
The same procedure will be followed as above, but saline will be injected instead of onabotA
Drug: Sodium Chloride 0.9% for Injection, Preservative Free
Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Also known as: Botox
intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Also known as: Saline
Change in Number of TN Attacks per week
Frequency of TN attacks before and after onabotA injection over a seven day period
Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment))
Change in PROMIS Computer Adaptive Tests (PROMIS PROFILE CAT V1.0 -29)
Computer adaptive tests (CATs) assess anxiety, depression, fatigue, pain interference, physical function, sleep disturbance and ability to participate in social roles and activities, and pain intensity.
Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)
Change in Severity of Attacks Based using the numerical rating scale (NRS)
Average severity of attack over a 7 day period
Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)
Change In Baseline Pain Average using the numerical rating scale (NRS)
baseline pain average over a seven day period
Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)
Change In Acute Medication Use
Number of doses of any acute medication use over a 7 day period
Time frame: compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)
Change In Patient Global Impression of Change
A single self administered question given at week 4
Time frame: week 4
Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A